Gilead Sciences Operating Income 2010-2022 | GILD

Gilead Sciences annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Gilead Sciences operating income for the quarter ending March 31, 2022 was $0.197B, a 93.18% decline year-over-year.
  • Gilead Sciences operating income for the twelve months ending March 31, 2022 was $7.225B, a 58.48% increase year-over-year.
  • Gilead Sciences annual operating income for 2021 was $9.918B, a 143.63% increase from 2020.
  • Gilead Sciences annual operating income for 2020 was $4.071B, a 5.04% decline from 2019.
  • Gilead Sciences annual operating income for 2019 was $4.287B, a 47.72% decline from 2018.
Gilead Sciences Annual Operating Income
(Millions of US $)
2021 $9,918
2020 $4,071
2019 $4,287
2018 $8,200
2017 $14,124
2016 $17,633
2015 $22,193
2014 $15,265
2013 $4,524
2012 $4,010
2011 $3,790
2010 $3,962
2009 $3,529
Gilead Sciences Quarterly Operating Income
(Millions of US $)
2022-03-31 $197
2021-12-31 $940
2021-09-30 $3,842
2021-06-30 $2,246
2021-03-31 $2,890
2020-12-31 $2,651
2020-09-30 $2,001
2020-06-30 $-2,983
2020-03-31 $2,402
2019-12-31 $1,093
2019-09-30 $-1,473
2019-06-30 $2,430
2019-03-31 $2,237
2018-12-31 $1,144
2018-09-30 $2,623
2018-06-30 $2,280
2018-03-31 $2,153
2017-12-31 $2,291
2017-09-30 $3,812
2017-06-30 $4,254
2017-03-31 $3,767
2016-12-31 $4,045
2016-09-30 $4,399
2016-06-30 $4,538
2016-03-31 $4,651
2015-12-31 $5,621
2015-09-30 $5,585
2015-06-30 $5,616
2015-03-31 $5,371
2014-12-31 $4,330
2014-09-30 $3,480
2014-06-30 $4,412
2014-03-31 $3,043
2013-12-31 $1,197
2013-09-30 $1,148
2013-06-30 $1,154
2013-03-31 $1,025
2012-12-31 $1,107
2012-09-30 $1,044
2012-06-30 $1,059
2012-03-31 $800
2011-12-31 $867
2011-09-30 $1,004
2011-06-30 $1,017
2011-03-31 $902
2010-12-31 $829
2010-09-30 $979
2010-06-30 $993
2010-03-31 $1,161
2009-12-31 $1,065
2009-09-30 $894
2009-06-30 $761
2009-03-31 $808
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $80.075B $27.305B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00